Selecta Biosciences (NASDAQ:SELB) reported Q2 EPS of $0.06, $0.14 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $39.27 million versus the consensus estimate of $13.78 million.
Selecta Biosciences (NASDAQ:SELB) reported Q2 EPS of $0.06, $0.14 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $39.27 million versus the consensus estimate of $13.78 million.